Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMO9S5P)

Drug Name

UCCF-029 Drug Info

Synonyms

2-Pyridin-4-yl-benzo[h]chromen-4-one; UCCF-029; 2110-25-0; CHEMBL177991; 2-(pyridin-4-yl)-4H-benzo[h]chromen-4-one; BAS 12813734; AC1MKUU0; MLS001209162; ZINC9006; SCHEMBL4069839; GTPL4335; CTK7H2722; DTXSID20390354; CHEBI:116557; HMS2841G23; BDBM50159612; 2-(4-pyridyl)benzo[h]chromen-4-one; 2-pyridin-4-ylbenzo[h]chromen-4-one; AKOS000507523; MCULE-4590967836; 2-(pyridin-4-yl)benzo[h]chromen-4-one; SMR000525005; TR-043515; ST50294170; EC-000.1914; 4-(4-Oxo-4H-benzo[h]chromen-2-yl)-pyridinium; J-013846

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 3163532
ChEBI ID: CHEBI:116557
CAS Number: CAS 2110-25-0
TTD Drug ID: DMO9S5P

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting cAMP-dependent chloride channel (CFTR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ivacaftor	DMZC1HS	Cystic fibrosis	CA25	Approved	[3]
Crofelemer	DM4AMQZ	HIV-associated diarrhoea	1A2Z	Approved	[4]
Tezacaftor and ivacaftor	DMY62FC	Acute lung injury	NB32.3	Approved	[5]
VX-661	DMJBXO3	Cystic fibrosis	CA25	Phase 3	[6]
ABBV-2222	DM4ZLTY	Cystic fibrosis	CA25	Phase 2	[7]
GLPG-1837	DMOCRYB	Cystic fibrosis	CA25	Phase 2	[7]
iOWH032	DM5TMYC	Diarrhea	ME05.1	Phase 2	[8]
Lumacaftor	DMCLWDJ	Cystic fibrosis	CA25	Phase 2	[9]
QBW251	DMQ5APT	Chronic obstructive pulmonary disease	CA22	Phase 2	[10]
ABBV-3067	DMB01L5	Cystic fibrosis	CA25	Phase 1	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
cAMP-dependent chloride channel (CFTR)	TTRLZHP	CFTR_HUMAN	Activator	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4335).
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 707).
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
5	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
6	CFTR Modulators for the Treatment of Cystic Fibrosis. P T. 2014 Jul;39(7):500-11.
7	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
8	Developing novel antisecretory drugs to treat infectious diarrhea. Future Med Chem. 2011 Aug;3(10):1317-25.
9	A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014 Jul;2(7):527-38.
10	Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251). J Cyst Fibros. 2021 Mar;20(2):250-256.